|Awarded On||February 21, 2018|
|Title||Rhabdomyosarcoma vulnerabilities: Prioritizing and extending to the clinic|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Stephen X Skapek|
Survival for children with certain types of cancer remains dismal despite many years of research. This is particularly true for children with rhabdomyosarcoma, the most common soft tissue sarcoma in children. Only about 1 in 5 children with metastatic or recurrent disease survive for three years, and this poor outlook has not improved despite many attempts to intensify chemotherapy and use new agents. Many experts feel that new insight into rhabdomyosarcoma biology is needed to light a path toward better therapy. Toward this goal, advances in DNA sequencing and computational analysis tools have enabled detailed studies of DNA within rhabdomyosarcoma, and much of that work has focused on ide...